Federal Register of Legislation - Australian Government

Primary content

Determinations/Health as made
This determination creates a new Medicare pathology item 73336 for the test of tumour tissue from a patient with unresectable stage III or stage IV metastatic cutaneous melanoma, in order to determine if the patient meets the requirements relating to BRAF V600 gene mutation status for access under the Pharmaceutical Benefits Scheme to the drug dabrafenib.
Administered by: Health
Registered 29 Nov 2013
Tabling HistoryDate
Tabled Senate04-Dec-2013
Tabled HR04-Dec-2013
Date of repeal 01 Nov 2014
Repealed by Health Insurance (Pharmacogenetic Testing) Revocation Determination 2014
Table of contents.

Health Insurance (Pharmacogenetic Testing) Determination 2013 (No. 1)

 

I, RICHARD BARTLETT, delegate of the Minister for Health, make this Determination under subsection 3C(1) of the Health Insurance Act 1973.

Dated 27 November 2013

 

 

 

__________________________

 

RICHARD BARTLETT

FIRST ASSISTANT SECRETARY

MEDICAL BENEFITS DIVISION

 

 

 

 


Contents

 

1.                Name of Determination                                                                       3

2.                Commencement                                                                                   3

3.                Authority                                                                                             3

4.                Interpretation                                                                                       3

5.                Treatment of a relevant service                                                            3

 

SCHEDULE –   SPECIFIED HEALTH SERVICES                                                4

 

 


Part 1                     Preliminary

1.                       Name of Determination

This Determination is the Health Insurance (Pharmacogenetic Testing)  Determination 2013 (No.1).

2.                       Commencement

This Determination commences on 1 December 2013.

3.           Authority

This Determination is made under the Health Insurance Act 1973.

4.           Interpretation

(1)    In this Determination:

         Act means the Health Insurance Act 1973.

relevant provision means a provision of the Act or of regulations made under the Act, or a provision of the National Health Act 1953 or of regulations made under that Act, that relates to professional services, medical services or items.

relevant service means a health service, as defined in subsection 3C(8)

of the Act, that is specified the Schedule to this Determination.

 

Note     Unless the contrary intention appears, expressions used in this determination have the same meanings as in the Act—see section 13 of the Legislative Instruments Act 2003.

(2)    Unless the contrary intention appears, in this Determination a reference to a provision of the Act or regulations made under the Act or the National Health Act 1953 or regulations made under the National Health Act 1953 as applied, adopted or incorporated in relation to specifying a matter is a reference to those provisions as in force from time to time and any other reference to provisions of an Act or regulations is a reference to those provisions as in force from time to time.

5.           Treatment of a relevant service

              A relevant service specified in the Schedule shall, for the purposes of each relevant provision, be treated as if:

(a)                    it were both a professional service and a medical service; and

(b)                   there was an item in Group 7 of the pathology services table that:

i.         related to the service; and

ii.        specified in respect of the service a fee in relation to each State being the fee specified in the Schedule.

 


SCHEDULE –         SPECIFIED HEALTH SERVICES

 

 

Item

Health Service

Fee for all States ($)

73336

A test of tumour tissue from a patient with unresectable stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib under the Pharmaceutical Benefits Scheme (PBS) are fulfilled.

 

230.95

 

Note    Subsection 3C(7) of the Act deems an internal territory to form part of the State of New South Wales.